Discovering new health technology
In the dynamic realm of health research, Hesperos, Inc., a pioneering biotechnology firm, is making groundbreaking strides with its Human-on-a-Chip® platform. This multi-organ microphysiological system, one of the world’s most advanced, is revolutionizing the way we approach drug development and disease treatment.
Human-on-a-Chip® stands out for its ability to replicate human biological functions. It’s a flexible and
customizable platform, incorporating various organs and barrier tissues, adaptable to mimic a wide range of human diseases. This innovation is particularly crucial in drug research, offering an unprecedented window into human responses to potential therapeutics, thereby significantly reducing the reliance on animal testing.
Human-on-a-Chip®’s ability to replicate human diseases, including rare ones, brings ethical and economic benefits. With over 7,000 known rare diseases, only a fraction has active research programs or existing animal models. This technology fills a critical gap, offering hope for treatment development, especially considering the FDA Modernization Act 2.0, which offers alternative pathways for new drug approvals.
Aston spoke to Dr James Hickman, founder and chief scientist at Hesperos Inc.
Ads help us keep this site online